Boehringer Ingelheim Opens AI and Machine Learning Centre in London — £150M Over a Decade 🔗

Boehringer Ingelheim has inaugurated an AI and machine learning centre in King's Cross, London, backed by a £150 million ($202.7 million) ten-year investment commitment. The centre will focus on computational models for disease biology, early-stage research decision support, and analysis of patient journeys and disease mechanisms. Approximately 50 AI specialists are expected to be hired by 2027. The London hub will operate alongside existing AI centres in the US, Austria, and Germany.

The location is deliberate: King's Cross has become one of the densest concentrations of life sciences and AI capability in Europe, adjacent to the Francis Crick Institute, Google DeepMind, and a significant cluster of biotech tenants. Boehringer is not building an AI experiment. It is building a permanent research function and anchoring it inside the ecosystem it needs to draw from.

Johnson & Johnson Partners with Viz.ai on Neurovascular AI Imaging 🔗

Johnson & Johnson has announced a partnership with Viz.ai to integrate AI-driven neurovascular imaging into its MedTech portfolio, alongside the acquisition of Atraverse Medical for transseptal access in minimally invasive cardiac procedures. The Viz.ai integration is the AI-specific move: Viz.ai's platform uses AI to analyze imaging data and accelerate time-to-treatment decisions in stroke and neurovascular emergencies. J&J is wiring this into its existing neurovascular device infrastructure.

The combination of Viz.ai's software layer with J&J's device and procedural install base gives the company a data asset that compound over time — every procedure through a J&J device that runs through Viz.ai adds to a training set that competitors without the same device market share cannot replicate. In high-acuity neurovascular care, where minutes determine outcomes, AI-assisted imaging decisions have direct clinical value that is measurable and defensible for reimbursement. This is the kind of integration that creates durable competitive position rather than a product feature.

Infinitus Launches No-Code AI Agent Builder for Healthcare and Pharma 🔗

Infinitus Systems has released Infinitus Studio, a no-code platform allowing healthcare payors and pharmaceutical companies to design, test, and deploy AI agents without programming. The platform connects to existing healthcare systems, includes scenario simulation before live deployment, and features a patent-pending Agent Response Control system for routing sensitive patient interactions — medication dosage inquiries, for example — to maintain compliance. Early deployments are reporting success rates exceeding 93% on the company's healthcare intelligence platform, with a claimed 90% reduction in deployment timelines versus custom development.

The no-code framing matters for pharma specifically because the teams managing patient engagement, market access, and commercial operations are not engineering functions. Tools that remove the engineering dependency from AI deployment shift the adoption curve dramatically.

Reduces validation cycle time by up to 80% through AI-powered document generation and automated traceability matrices

Real-time anomaly flagging during test execution detects GDP issues against approved SOPs before they become observations

Continuous audit readiness maintained across the full validation lifecycle, with 21 CFR Part 11 and Annex 11 compliance built in

WHO Europe: 74% of EU Countries Now Using AI-Assisted Diagnostics 🔗
The World Health Organization's European office has published its first comprehensive report on AI integration across all 27 EU member states, drawing on data from mid-2024 to early 2025. Seventy-four percent of EU countries are now using AI-assisted diagnostics across medical imaging and clinical decision-making. Sixty-three percent have deployed AI-powered chatbots for patient engagement. The report marks a shift in how AI in European healthcare is documented — from aspirational policy language to measured deployment data.

The signal: The question is no longer whether European health systems are adopting AI diagnostics, but which vendors will capture the reimbursement pathways, interoperability standards, and regulatory frameworks being constructed around adoption that is already underway. The market exists. The competition is now for the infrastructure layer around it.

EU Biotech Act II: 40 Industry Organizations Call for Biomanufacturing Legislation 🔗

A coalition of nearly 40 industry organizations across Europe has published a joint position paper calling for the EU's Biotech Act II, framing the absence of dedicated biomanufacturing legislation as a structural competitive disadvantage against the US, India, and China. The proposed Act would increase funding for biotech companies, simplify regulatory processes, and create dedicated pathways to scale biomanufacturing from innovation to industrial production.

The signal: The position paper explicitly includes AI and digital solutions as part of the biomanufacturing framework — the data infrastructure needed for AI-driven bioprocess optimization requires regulatory clarity that does not currently exist at EU level. For AI vendors operating in manufacturing and process development, this is the legislative moment to engage.